Highlights

• Glenmark secured exclusive commercialization rights for an oncology therapy across multiple international markets.
• Kaynes Semicon announced technology collaborations to support semiconductor manufacturing operations in India.
• NBCC received infrastructure and maintenance work orders aggregating ₹345.04 crore.

Indian companies across pharmaceuticals, electronics manufacturing, and infrastructure announced significant business developments on 16 December 2025, highlighting continued deal activity across sectors. Glenmark Specialty S.A. disclosed an international licensing agreement for a cancer therapy, Kaynes Technology India Limited announced strategic partnerships in semiconductor manufacturing, while NBCC (India) Limited received new work orders totalling over ₹345 crore in the ordinary course of business.

Glenmark Enters Exclusive Oncology Licensing Pact

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK), announced that it has entered an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI).

Aumolertinib is indicated for the treatment of non-small cell lung cancer (NSCLC). Under the agreement, Glenmark will receive exclusive rights to develop and commercialize the drug across several territories, including the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia and CIS regions, along with select Caribbean countries.

Hansoh Pharma will receive an upfront payment in the low double-digit million US dollars. The agreement also includes potential regulatory and commercial milestone payments that may cumulatively exceed USD 1 billion, in addition to tiered royalties based on net sales in the licensed territories.

Kaynes Semicon Signs Strategic Partnerships with Japanese Firms

Kaynes Technology India Limited (NSE:KAYNES), through its wholly owned subsidiary Kaynes Semicon Private Limited, announced two strategic partnerships with Japanese companies AOI Electronics Co., Ltd. and Mitsui & Co., Ltd.

The collaboration with AOI Electronics focuses on semiconductor back-end manufacturing technologies. AOI Electronics brings expertise in advanced packaging, panel-level packaging, and wafer-level redistribution layer (RDL) technologies. The partnership aims to support Kaynes Semicon’s upcoming semiconductor manufacturing operations in India and enable turnkey back-end solutions for global customers across automotive, industrial, consumer electronics, and communications segments.

The alliance with Mitsui & Co., Ltd. is intended to support supply chain development and global market access as part of Kaynes Semicon’s broader manufacturing plans.

NBCC Bags Infrastructure Orders Worth ₹345 Crore

NBCC (India) Limited (NSE:NBCC) informed exchanges that it has received work orders totaling approximately ₹345.04 crore (excluding GST).

The largest order, valued at ₹332.99 crore, is from the Indian Institute of Technology, Mandi, for project management consultancy services related to planning, design, and development of academic blocks, residential housing, and a student activity centre, including sports facilities.

In addition, NBCC received a ₹12.05 crore order for annual maintenance services at Kandla SEZ for the period from 1 January 2026 to 31 December 2026, covering multiple facility management services.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

Copyright 2026 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.